#i Series #MAaGI Medical #Tumor Therapy

Revolutionizing Cancer Treatment: MAaGI Medical's 'i' Series

In the summer of 2026, a pivotal event took place in Suzhou, China, where some of the brightest minds in interventional radiology gathered for the 20th Annual Scientific Meeting of the Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR 2026). Held from June 11 to 14 at the Suzhou International Expo Centre, this congress drew over a thousand elite scholars, showcasing innovations in medical treatments, particularly in oncology. Among the highlights of the event was the debut of MAaGI Medical's novel 'i' Series multimodal tumor therapy technology, which has gained significant attention globally.

Transforming Treatment for Solid Tumors

MAaGI Medical's pioneering technology aims to redefine the treatment of solid tumors—including those difficult-to-treat cases like liver and pancreatic cancers. The 'i' Series leverages a unique approach that alternates between cryogenic freezing and radiofrequency heating, applying precise thermal dosage control. This technique effectively destroys tumor cells and facilitates the release of tumor antigens, transforming traditionally immune-cold tumors into immune-hot ones that respond better to immunotherapy.

This innovative therapy has passed through a specially designed review pathway for innovative medical devices in China, receiving market approval based on the substantial clinical benefits it offers. Recent research featuring this technology has made headlines in leading journals and conferences, showcasing its incredible potential within the medical community.

Clinical Advancements

Recent findings presented by MAaGI Medical at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) revealed remarkable results for pancreatic cancer treatment; an 8-month increase in overall survival rates was recorded when combining multimodal therapy for transforming pancreatic tumors with conventional immunotherapy. This result represents a watershed moment in the treatment of pancreatic cancer, often deemed